Navigation Links
Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
Date:3/10/2008

initiated Phase 3 trials. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR5 inhibitors for the treatment of HIV. More information about the company and its product candidates can be found on its web site at http://www.avexa.com.au

Forward Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the demand for our testing products, including our Trofile Assay, the potential use of our Trofile Assay for patient selection for the class of HIV drugs known as CCR5 antagonists, the size and timing of Avexa's clinical trials utilizing our products, the outlook for Avexa's investigational drug mentioned in this release and for our testing products, expected protection provided by patents, possible regulation of our products by the FDA. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use a molecular diagnostic for patient selection for CCR5 antagonists or other HIV drugs; whether larger confirmatory clinical studies will confirm the results of initial studies; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for HIV drugs, such as Avexa's drug mentioned in this release; the risk that our Trofile Assay may not be utilized for patient use with CCR5 inhibitors; our ability to successfully conduct clinical studies and the results obtained from those studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our reven
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... One of the major revolutions taking place in healthcare ... practice of using genomic and other molecular analyses to ... diagnostics—laboratory analyses that inform the practice of personalized medicine—will ... fall, AACC ,s first ever virtual conference ... field and the novel technologies driving it forward, all ...
(Date:8/1/2014)... August 1, 2014 According to ... "Biophotonics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 25.16 billion in 2013, which is ... at a CAGR of 10.4% from 2014 to 2020. ... http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate early ...
(Date:8/1/2014)... Toronto, Canada (PRWEB) August 01, 2014 ... what should it cost? This webinar will discuss how ... construction. , Join speakers Bob Allen, Senior Director ... Director of Process Engineering at Fluor Industrial Services, and ... supporting Manufacturing Asset Planning at Amgen, as they provide ...
(Date:8/1/2014)... RUTHERFORD, N.J., Aug. 1, 2014 Cambrex Corporation (NYSE: ... ended June 30, 2014. Highlights ... $61.6 million in the same period last year. , ... $11.4 million in the same period last year (see table ... 2014 sales guidance increased, excluding the impact of foreign currency, ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16
... Inc., a consulting firm,providing outcomes research and health ... announces the addition of,Anthony J. Vita, MD, MPH ... clinical,professionals. The specialized background of these two practitioners ... directly to those clients,seeking to enhance the clinical ...
... Palatin Technologies,Inc. (Amex: PTN ) will announce its ... 2007 before the open of the U.S. financial,markets. ... audio webcast,hosted by Palatin,s executive management team on November ... operations in greater detail and provide,an update on corporate ...
... SOUTH SAN FRANCISCO, Calif., Nov. 5 Exelixis,Inc. ... for the third quarter,ended September 30, 2007. ... were $26.8 million,compared to $23.5 million for the ... 2006 to 2007 was primarily due to revenue ...
Cached Biology Technology:EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD 2Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 3Exelixis Announces Third Quarter 2007 Financial Results and Business Update 4Exelixis Announces Third Quarter 2007 Financial Results and Business Update 5Exelixis Announces Third Quarter 2007 Financial Results and Business Update 6Exelixis Announces Third Quarter 2007 Financial Results and Business Update 7Exelixis Announces Third Quarter 2007 Financial Results and Business Update 8
(Date:8/1/2014)... NY, August 1, 2014Lesbian, gay, bisexual, and transgender individuals ... same problems as some of their heterosexual and cisgendered ... often face additional physiological and legal challenges to ... advances in assisted reproduction options is presented in the ... Possibilities ," published in LGBT Health ...
(Date:8/1/2014)... eye diseases is tricky enough. Knowing what causes them ... Now, University of Iowa researchers have created the most ... human eye long associated with blinding diseases, such as ... of proteins in the choroid, which supplies blood and ... By seeing differences in the abundance of proteins in ...
(Date:8/1/2014)... Sieve elements are a key component of phloem, the ... wide range of signalling molecules. Elongated cylindrical cells are ... arranged end-to-end to form sieve tubes which in turn ... "Sieve elements are very special cells which play ... very little has been known about their differentiation," says ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2A map for eye disease 2Developmental regulation of important plant phloem components discovered 2
... years, researchers have worked to develop a number of ... vaccines are not intended to prevent cancer; rather, they ... Unlike traditional chemotherapy, vaccines have relatively low toxicity and, ... these vaccines have rarely been designed to directly stimulate ...
... physics to show how our circadian clocks manage to ... , In an article appearing March 13 in the ... Federale de Lausanne demonstrate that the stability of cellular ... studies in families affected by advanced sleep phase syndrome. ...
... role in the development of the placenta, the organ that ... fetus during pregnancy, and perhaps in miscarriages. , Those ... gene in mice. In humans, this gene, when mutated, raises ... retinoblastoma. Two decades ago, it was identified as the first ...
Cached Biology News:Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 2Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 3Keeping the body in sync -- The stability of cellular clocks 2Tumor-suppressor gene is critical for placenta development 2Tumor-suppressor gene is critical for placenta development 3
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... Synthetic peptide derived from an internal region ... target of rapamycin FRAP RAFT1 RAPT1). ... On Western blots it identifies the ... Human (positive control: HEK293 cell lysates). Based ...
...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: